Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor

Molecular and Cellular Biochemistry

Volumn 183, Issue 1-2, 1998, Pages 11-23

  Kovalszky, Ilona ^a   Dudás, József ^a   Oláh Nagy, Julia ^a   Pogány, Gábor ^a   Töváry, József ^a   Timár, József ^a   Kopper, László ^a   Jeney, András ^a   Iozzo, Renato V ^b,c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Glycosaminoglycans; Heparan sulfate; Topoisomerase I

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DNA; DNA TOPOISOMERASE; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARIN;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; DNA SUPERCOILING; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL LINE; LIVER; PROTEIN LOCALIZATION;

CELL NUCLEUS; DNA TOPOISOMERASES, TYPE I; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCANS; HEPARIN; HEPARITIN SULFATE; HUMANS; LIVER; NUCLEAR PROTEINS; POLYETHYLENE GLYCOLS; TUMOR CELLS, CULTURED; U937 CELLS;

EUKARYOTA; MAMMALIA;

EID: 7144242315     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006898920637     Document Type: Article

References (73)

1. Geliert M: DNA topoisomerases. Ann Rev Biochem 50: 879-910, 1981
2. Wang JC: DNA topoisomerases. Ann Rev Biochem 54: 665-697, 1985
3. Stewart AF, Schültz G: Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene. Cell 50: 1109-1117, 1987
4. Gilmour DS, Elgin SCR: Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin. Mol Cell Biol 7: 141-148, 1987
5. Zhang H, Wang JC, Liu LF: Involvement of DNA topisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 85: 1060-1064, 1988
6. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SCR: Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81: 6958-6962, 1984
7. Muller MT, Pfund WP, Mehta VB, Trask DK: Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J4: 1237-1243, 1985
8. Egyházi E, Durban E: Microinjection of anti-topoisomerase I immunoglobulin G into nuclei of chironomus tentans salivary gland cells leads to blockage of transcription elongation. Mol Cell Biol 7: 4308-4316, 1987
9. Kim RA, Wang JC: Function of DNA topoisomerases as replication swivels in saccharomyces cerevisiae. J Mol Biol 208: 257-267, 1989
10. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989
11. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993
12. van der Zee AGJ, Hollema H, deJong S, Boonstra H, Gouw A, Willemse PHB, Zijistra JG, deVries EGE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991
13. vander Zee AGJ, deJong S, Keith WN, Hollema H, Boonstra H, deVries EGE: Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54: 749-755, 1994
14. Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T, Nagao S: Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 53: 97-103, 1993
15. Gromova II, Kjeldsen E, Svejstrup JQ, Aisner J, Christiansen K, Westergaard O: Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res 21: 593-600, 1993
16. Madelaine I, Prost S, Naudin A, Riou G, Lavelle F, Riou J-F: Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 45: 339-348, 1993
17. Camilloni G, Di Martino E, Caserta M, di Mauro E: Eukaryotic DNA topoisomerase I reaction is topology dependent. Nucleic Acids Res 16: 7071-7085, 1988
18. Camilloni G, Di Martino E, di Mauro E, Caserta M: Regulation of the function of eukaryotic DNA topoisomerase I: Topological conditions for inactivity. Proc Natl Acad Sci USA 86: 3080-3084, 1989
19. Stewart L, Ireton GC, Parker LH, Madden KR, Champoux JJ: Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 271: 7593-7601, 1996
20. Samuels DS, Shimizu Y, Shimizu N: Protein kinase C phosphorylates DNA topoisomerase I. FEBS Lett 259: 57-60, 1989
21. Pommier Y, Kerrigan D, Hartman KD, Glazer RI: Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem 265: 9418-9422, 1990
22. Esther A, Iftach S, Esther P: Inhibition of moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors. FEBS Lett 341: 99-103, 1994
23. Krupitza G, Cerutti P: ADP-ribosylation of ADPR-transferase and topoisomerase I in intact mouse epidermal cells JB6. Biochemistry 28: 2034-2040, 1989
24. Rossi F, Labourier E, Forné T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunei C, Tazi J: Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381: 80-82, 1996
25. Ishii K, Katase A, Andoh T, Seno N: Inhibition of topoisomerase I by heparin. Biochem Biophys Res Commun 104: 541-547, 1982
26. Anderiuzzi D, Pedrini AM: Structural similarities between M. luteus and E. coli DNA topoisomerase I. Biochem Biophys Res Comm 192: 657-664, 1993
27. Ishihara M, Fedarko NS, Conrad HE: Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 261: 13575-13580, 1986
28. Fedarko NS, Conrad HE: A unique heparan sulfate in the nuclei of hepatocytes: Structural changes with the growth state of the cells. J Cell Biol 102: 587-599, 1986
29. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951-3957, 1991
30. Aviezer D, Levy E, Safran M, Svahn C, Buddecke E, Schmidt A, David G, Vlodavsky I, Yayon A: Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem 269: 114-121, 1994
31. Fedarko NS, Ishihara M, Conrad HE: Control of cell division in hepatoma cells by exogenous heparan sulfate proteoglycan. J Cell Physiol 139: 287-294, 1989
32. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL: Trans-repressor activity of nuclear glycosaminoglycans on fos and jun/AP-1 oncoprotein-mediated transcription. J Cell Biol 116: 31-42, 1992
33. Grammatikakis N, Grammatikakis A, Yoneda M, Yu Q, Banerjee SD, Toole BP: A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein, Cdc37. J Biol Chem 270: 16198-16205, 1995
34. Esko JD: Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 3: 805-816, 1991
35. Tyrrell DJ, Ishihara M, Rao N, Home A, Kiefer MC, Stauber GB, Lam LH, Stack RJ: Structure and biological activities for a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 268: 4684-4689, 1993
36. Turnbull JE, Gallagher JT: Heparan sulphate: Functional role as a modulator of fibroblast growth factor activity. Biochem Soc Trans 21: 477-482, 1993
37. Faham S, Hileman RE, Fromm JP, Linhardt RJ, Rees DC: Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120, 1996
38. Kovalszky I, Pogány G, Molnár G, Jeney A, Lapis K, Karácsonyi S, Szécsény A, Iozzo RV: Altered glycosaminoglycans composition in reactive and neoplastic human liver. Biochem Biophys Res Comm 167: 883-890, 1990
39. Debbage PL, Lange W, Hellmann T, Gabius HJ: Detection of receptors for sulfated polysaccharides in human placenta by biotinylated probes. J Histochem Cytochem 36: 1097-1102, 1988
40. Murata K, Ochiai Y, Akashio K: Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. Gastroenterology 89: 1248-1257, 1985
41. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
42. Bitter T, Muir HM: A modified uronic acid carbazole reaction. Anal Biochem 4: 330-334, 1962
43. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989
44. Duguet M, Lavenot C, Harper F, Mirambeau G, De Recondo A-M: DNA topoisomerases from rat liver: Physiological variations. Nucleic Acids Res 11: 1059-1075, 1983
45. Sullivan DM, Latham MD, Rowe TC, Ross WE: Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28: 5680-5687, 1989
46. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970
47. Volpi N, Cusmano M, Venturelli T: Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1243: 49-58, 1995
48. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992
49. Iozzo RV, Bolender RP, Wight TN: Proteoglycan changes in the intercellular matrix of human colon carcinoma. Lab Invest 47: 124-138, 1982
50. Iozzo RV, Cohen I: Altered proteoglycan gene expression and the tumor stroma. Experientia 49: 447-455, 1993
51. Gallagher JT: The extended family of proteoglycans: Social residents of the pericellular zone. Curr Opin Cell Biol 1: 1201-1218, 1989
52. Iozzo RV: Presence of unsulfated heparan chains on the heparan sulfate proteoglycan of human colon carcinoma cells. Implications for heparan sulfate proteoglycan biosynthesis. J Biol Chem 264: 2690-2699, 1989
53. Esko JD, Rostand KS, Weinke JL: Tumor formation dependent on proteoglycan biosynthesis. Science 241: 1092-1096, 1988
54. Hiscock DR, Yanagishita M, Hascall VC: Nuclear localization of glycosaminoglycans in rat ovarian granulosa cells. J Biol Chem 287-294, 1989
55. Moczar E, Raulais D, Poupon MF, Moczar M: Heparin-binding sites of rhabdomyoma cells with low and high metastatic capacity. Invasion Metastasis 11: 158-165, 1991
56. Sanderson RD, Tumbull JE, Gallagher JT, Lander AD: Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269: 13100-13106, 1994
57. Lee MK, Lander AD: Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: Development of a sensitive electrophoretic approach. Proc Natl Acad Sci USA 88: 2768-2772, 1991
58. Turnbull JE, Fernig DG, KeY, Wilkinson MC, Gallagher JT: Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267: 10337-10341, 1992
59. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT: Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 269: 11216-11223, 1994
60. Riccio A, Pedone PV, Lund LR, Olesen T, Olsen HS, Andreasen PA: Transforming growth factor β1-responsive element: Closely associated binding sites for USF and CAAT-binding transcription factor-nuclear factor I in the type I plasminogen activator inhibitor gene. Mol Cell Biol 12: 1846-1855, 1992
61. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848, 1991
62. Hill DJ, Logan A: Cell cycle-dependent localization of immunoreactive basic fibroblast growth factor to cytoplasm and nucleus of isolated ovine fetal growth plate chondrocytes. Growth Factors 7: 215-231, 1992
63. r 18,000 basic fibroblast growth factor: Site-directed mutagenesis of a putative nuclear translocation sequence. Growth Factors 9: 269-278, 1993
64. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 81: 631-638, 1993
65. Renko M, Quarto N, Morimoto T, Rifkin NB: Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol 144: 108, 1990
66. Tessier S, Neufeld G: Basic fibroblast growth factor accumulates in the nuclei of various bFGF-producing cell types. J Cell Physiol 145: 310, 1990
67. Riese J, Zeller P, Dono R: Nucleo-cytoplasmic translocation and secretion of fibroblast growth factor-2 during avian gastrulation. Mech Develop 49: 13-22, 1995
68. Rifkin DB, Moscatelli D, Roghani M, Nagano Y, Quarto N, Klein S, Bikfalvi A: Studies on FGF-2: Nuclear localization and function of high molecular weight forms and receptor binding in the absence of heparin. Mol Repro Dev 39: 102-105, 1994
69. Vilgrain I, Gonzalez AM, Baird A: Phosphorylation of basic fibroblast growth factor (FGF-2) in the nuclei of SK-Hep-1 cells. FEBS Lett 331 : 228-232, 1993
70. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin collagenase, plasmin and heparanases. J Biol Chem 271: 10079-10086, 1996
71. Iozzo RV, Cohen IR, Grässel S, Murdoch AD: The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302: 625-639, 1994
72. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A: Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79: 1005-1013, 1994
73. Aviezer D, Iozzo RV, Noonan DM, Yayon A: Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense CDNA. Mol Cell Biol 17: 1938-1946, 1997